Giuseppe Rosiello

Giuseppe Rosiello

Auto-generated profile, based on publicly available information

Giuseppe Rosiello

Unit of Urology, Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2022 in Journal of Endourology
Verified
Journal Article
Closed access
RFRui Farinha
Rui Farinha
SPStefano Puliatti
Stefano Puliatti
EMElio Mazzone
Elio Mazzone
MAMarco Amato
Marco Amato
GRGiuseppe Rosiello
Giuseppe Rosiello
AMAlexandre Mottrie
Alexandre Mottrie
Purpose: To summarize the scientific published literature on new robotic surgical platforms with potential use in the urological field, reviewing their evolution from presentation until the present day. Our goal is to describe the current characteristics and possible prospects for these platforms. Materials and Methods: A nonsystematic search of the PubMed, Cochrane library's Central, EMBASE, MEDLINE, and Scopus databases was conducted to identify scientific literature about new robotic platforms other than the Da Vinci ® system, reviewing their evolution from inception until December 2020. Only English language publications were included. The following keywords were used: “new robotic platforms,” “Revo-I robot,” “Versius robot,” and “Senhance robot.” All relevant English-language original studies were analyzed by one author (R.F.) and summarized after discussion with an independent third party (E.M., S.Y., S.P., and M.A.). Results: Since 1995, Intuitive Surgical, Inc., with the Da Vinci surgical system, is the leading company in the robotic surgical market. However, Revo-I ® , Versius ® , and Senhance ® are the other three platforms that recently appeared on the market with available articles published in peer-reviewed journals. Among these three new surgical systems, the Senhance robot has the most substantial scientific proof of its capacity to perform minimally invasive urological surgery and as such, it might become a contender of the Da Vinci robot. Conclusions: The Da Vinci surgical platform has allowed the diffusion of robotic surgery worldwide and showed the different advantages of this type of technique. However, its use has some drawbacks, especially its price. New robotic platforms characterized by unique features are under development. Of note, they might be less expensive compared with the Da Vinci robotic system. We found that these new platforms are still at the beginning of their technical and scientific validation. However, the Senhance robot is in a more advanced stage, with clinical studies supporting its full implementation.

1 May 2021 in European Urology Focus
Verified
Journal Article
Closed access
CPCarlotta Palumbo
Carlotta Palumbo
APAngela Pecoraro
Angela Pecoraro
SKSophie Knipper
Sophie Knipper
GRGiuseppe Rosiello
Giuseppe Rosiello
SLStefano Luzzago
Stefano Luzzago
PKPierre I. Karakiewicz
Pierre I. Karakiewicz

1 June 2022 in Journal of Endourology
Verified
Journal Article
Closed access
AVAlessandro Veccia
Alessandro Veccia
UCUmberto Carbonara
Umberto Carbonara
HDHooman Djaladat
Hooman Djaladat
RMReza Mehrazin
Reza Mehrazin
DEDaniel D Eun
Daniel D Eun
RARiccardo Autorino
Riccardo Autorino
Purpose: To compare the outcomes of robotic radical nephroureterectomy (RRNU) and laparoscopic radical nephroureterectomy (LRNU) within a large multi-institutional worldwide dataset. Materials and Methods: The ROBotic surgery for Upper tract Urothelial cancer STudy (ROBUUST) includes data from 17 centers worldwide regarding 877 RRNU and LRNU performed between 2015 and 2019. Baseline features, perioperative and oncologic outcomes, were included. A 2:1 nearest-neighbor propensity-score matching with a 0.001 caliper was performed. A univariable and a multivariable logistic regression model were built to evaluate the predictors of a composite “tetrafecta” outcome defined as occurrence of bladder cuff excision+LND+no complications+negative surgical margins. Results: After matching, 185 RRNU and 91 LRNU were assessed. Patients in the RRNU group were more likely to undergo bladder cuff excision (81.9% vs 63.7%; p < 0.001) compared to the LRNU group. A statistically significant difference was found in terms of overall postoperative complications ( p = 0.003) and length of stay ( p < 0.001) in favor of RRNU. Multivariable analysis demonstrated that LRNU was an independent predictor negatively associated with achievement of “tetrafecta” (odds ratio: 0.09; p = 0.003). Conclusions: In general, RRNU and LRNU offer comparable outcomes. While the rate of overall complications is higher for LRNU in this study population, this is mostly related to low-grade complications, and therefore with more limited clinical relevance. RRNU seems to offer shorter hospital stay, but this might also be related to the different geographical location of participating centers. Overall, the implementation of robotics might facilitate achievement of a “tetrafecta” outcome as defined in the present study.

18 March 2020 in Prostate Cancer and Prostatic Diseases
Verified
Journal Article
Closed access
PDF file
GRGiuseppe Rosiello
Giuseppe Rosiello
CPCarlotta Palumbo
Carlotta Palumbo
SKSophie Knipper
Sophie Knipper
MDMarina Deuker
Marina Deuker
LSLara Franziska Stolzenbach
Lara Franziska Stolzenbach
PKPierre I. Karakiewicz
Pierre I. Karakiewicz

6 February 2022 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
GRGiuseppe Rosiello
Giuseppe Rosiello
ALAlessandro Larcher
Alessandro Larcher
GFGiuseppe Fallara
Giuseppe Fallara
CGCristina Giancristofaro
Cristina Giancristofaro
AMAlberto Martini
Alberto Martini
UCUmberto Capitanio
Umberto Capitanio

27 February 2020 in Journal of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
GRGiuseppe Rosiello
Giuseppe Rosiello
CPCarlotta Palumbo
Carlotta Palumbo
SKSophie Knipper
Sophie Knipper
APAngela Pecoraro
Angela Pecoraro
SLStefano Luzzago
Stefano Luzzago
PKPierre I. Karakiewicz
Pierre I. Karakiewicz